Research Article

Circular RNA cir-ITCH Is a Potential Therapeutic Target for the Treatment of Castration-Resistant Prostate Cancer

Shoubin Li¹,², Chunhong Yu,² Yunxia Zhang,² Junjiang Liu,² Yi Jia,² Fuzhen Sun,² Panying Zhang,² Jingpo Li,² Liuxiong Guo,² Helong Xiao,² Fei Gao,² Xinna Deng,² Ziqi Cai,³ and Jianhui Cai¹,²,³

¹Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei 050017, China
²Department of Urology, Health Examination Center, Obstetrics and Gynecology, and Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, China
³Hebei Engineering Technology Research Center for Cell Therapy, Hebei HOFOY Biotech Corporation Ltd., Shijiazhuang, Hebei 050000, China

Correspondence should be addressed to Jianhui Cai; jianhuicai2001@163.com

Received 16 March 2020; Revised 5 July 2020; Accepted 24 July 2020; Published 21 August 2020

Academic Editor: Jane Hanrahan

Copyright © 2020 Shoubin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

cir-ITCH, a well-known tumor-suppressive circular RNA, plays a critical role in different cancers. However, its expression and functional role in prostate cancer (PCa) are unclear. Herein, we explored the potential mechanism and tumor-inhibiting role of cir-ITCH in PCa. Using reverse transcriptase polymerase chain reaction assay, we analyzed the expression of cir-ITCH in PCa and paired adjacent nontumor tissue samples resected during surgical operation, as well as in two cell lines of human PCa (LNCaP and PC-3) and the immortalized normal prostate epithelial cell line (RWPE-1). Cell viability and migration of PCa cell lines were evaluated using CCK-8 and wound-healing assays. Expression of key proteins of the Wnt/β-catenin and PI3K/AKT/mTOR pathways was detected using western blotting. We found that cir-ITCH expression was typically downregulated in the tissues and cell lines of PCa compared to that in the peritumoral tissue and in RWPE-1 cells, respectively. The results showed that cir-ITCH overexpression significantly inhibits the proliferation, migration, and invasion of human PCa cells and that reciprocal inhibition of expression occurred between cir-ITCH and miR-17. Proteins in the Wnt/β-catenin and PI3K/AKT/mTOR pathways were downregulated by overexpression of cir-ITCH both in androgen receptor-positive LNCaP cells and androgen receptor-negative PC-3 cells. Taken together, these data demonstrated that cir-ITCH plays a tumor-suppressive role in human PCa cells, partly through the Wnt/β-catenin and PI3K/AKT/mTOR pathways. Thus, cir-ITCH may serve as a novel therapeutic target for the treatment of PCa, especially castration-resistant prostate cancer.

1. Introduction

Since the androgen receptor (AR) signaling plays a critical role in the development and progression of prostate cancer (PCa), androgen deprivation therapy (ADT) or AR antagonists remain the standard treatment for PCa patients. However, almost all patients eventually progress to castration-resistant prostate cancer (CRPC), which is resistant to therapy [1]. The main factors accountable for the growth of CRPC are relevant to the AR pathway [2–4]. Although nearly half of the men with CRPC respond to novel hormonal agents such as abiraterone or enzalutamide, AR splice variants may still cause resistance [5]. Therefore, new targets independent of AR are necessary for the treatment of CRPC.

Circular RNA (circRNA) is a novel class of endogenous noncoding RNAs formed by a covalently closed loop [6]. Current evidence revealed that circRNAs may enhance or suppress cancer progression by suppressing miRNA species associated with the development of tumors [7].

cir-ITCH is a well-known circRNA that sponges different miRNAs and regulates the Wnt/β-catenin pathway. In addition, it has an inhibitory role in the malignancies of the
colorectum [8], lung [9], esophagus [10], and bladder [11]. However, its expression and functional role in prostate cancer, especially in CRPC, are not well demonstrated. We thus clarified its role in two different PCa cell lines (LNCaP and PC-3) representing hormone-sensitive PCa and CRPC, respectively.

### 2. Materials and Methods

#### 2.1. Clinical Samples.
Ten pairs of primary prostate cancer tissues and matched adjacent nontumor tissue samples were obtained from the Department of Urology, Hebei General Hospital, between January and December 2018, and were snap-frozen in liquid nitrogen and stored at -80°C until RNA extraction. All patients involved in the study provided their written informed consent. The study protocol was approved by the Ethics Committee of Hebei General Hospital.

#### 2.2. Cell Culture.
An immortalized normal prostate epithelial cell line (RWPE-1) and two PCa cell lines (LNCaP, PC-3) were purchased from the Chinese Academy of Sciences. The two PCa cell lines were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum while RWPE-1 cells were cultured in Prostate Epithelial Cell Medium-PRF (ScienCell, Carlsbad, CA, USA). All cells were incubated at 37°C with an atmosphere with 5% CO2.

#### 2.3. Circular RNA Plasmid Construction and Transient Transfections.
To overexpress human cir-ITCH (hsa_circ_0001141), cDNA was synthesized by GenScript Biotech (Nanjing, China) and cloned into pLC5-ciR (Geneseed Biotech, Guangzhou, China). Lentivirus was constructed by Wanleibio (Shenyang, China). For cell proliferation, qRT-PCR, migration, and invasion assays and experiments to verify the interaction between cir-ITCH and miR-17-5p, LNCaP, and PC-3 cells were treated with different transient transfections agents (GFP, cir-ITCH, miR-17, and cir-ITCH + miR-17). For immunoblot, LNCaP and PC-3 cells were divided into four groups according to different treatments (Figure 1). The dosage of dihydrotestosterone (DHT) was 10 nM and that of Bicalutamide (Casodex) was 10 μM. Transfection was performed as previously described according to the manufacturer’s instructions [12].

#### 2.4. RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).
Total RNA was isolated from tissues and cells using TriPure reagent (BioTeke, Beijing, China), according to the manufacturer’s protocol. The concentration of RNA in each sample was determined by ultraviolet spectrophotometer NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was synthesized using Super M-MLV reverse transcriptase (BioTeke, Beijing, China), and qRT-PCR for circRNA was performed on Exicycler 96 (Bioneer, Seoul, Korea) using primers (Sango Biotech, China) listed in Table 1. U6 and β-actin were used as internal controls for miRNA and mRNA detection, respectively. Each sample was replicated three times, and data was analyzed by comparing CT values [13].

#### 2.5. Cell Proliferation Assay.
Transfected cells were seeded into 96-well plates for cell proliferation experiments (4000 cells per well). Cell viability was measured using the cell counting kit 8 (CCK-8) system (Wanleibio, Shenyang, China), 0, 24, 48, and 72 hours after seeding. Each group consisted of six replicates. Three independent experiments were performed.
2.6. Migration and Invasion Assays. The wound-healing assay was conducted 24 hours after transfection to evaluate cell migration. A linear wound was created with a pipette tip across the confluent cell layer 1 h after treatment with 1 μg/mL mitomycin C. After two washing steps with serum-free medium, the cells were cultured at 37°C in an incubator in the presence of 5% CO2 for 24 h. Wound sizes were observed and measured before incubation and 24 h later.

In the invasion assay, the method described in a previous study [11] was used. Approximately 2×10^4 transfected cells were seeded into the upper chambers of each Transwell, which was coated with Matrigel (Corning, USA). Medium containing 30% FBS was added to the lower chamber. The cells were incubated at 37°C with 5% CO2 for 24 h. After incubation, the cells in the top chamber were wiped off with a cotton swab, and the cells on the lower surface were fixed with methanol, stained with 0.1% crystal violet, and photographed at 100x magnification under a microscope (Olympus, Japan). The number of cells in each sample was counted in five visual fields, and the average number was recorded.

2.7. Western Blotting. Protein extracts were obtained from cell lysates and quantified using the bicinchoninic acid (BCA) analysis method (Wanleibio, Shenyang, China). Proteins were separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. (Merck Millipore, Billerica, MA, USA). After incubation with high-affinity antibodies (anti-p21 (1:500), anti-PTEN (1:500), anti-AR (1:500), anti-mTOR (1:500), anti-p-mTOR (1:500), anti-AKT (1:500), anti-p-AKT (1:500), and anti-β-actin antibody (1:1000) (Wanleibio, Shenyang, China), the membranes were incubated with a secondary antibody (1:5000, Wanleibio, Shenyang, China). After incubation, ECL luminescent solution (Wanleibio, Shenyang, China) was evenly added to the PVDF membranes, these membranes were loaded onto the cassette and exposed in a darkroom. After washing, signals were detected and analyzed using the Gel-Pro-Analyzer software.

2.8. Statistical Analysis. The SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The data were expressed as mean ± SD. Data differences between two groups were analyzed using the Student’s t-test. A significance level was defined as P < 0.05.

3. Results

3.1. cir-ITCH Is Downregulated in PCa. Firstly, we examined the expression of cir-ITCH in 10 pairs of PCa tissues and matched adjacent normal tissues using qRT-PCR. Results indicated that cir-ITCH expression was significantly decreased in PCa tissues, compared to that in the matched adjacent normal tissues (Figure 2(a)). Additionally, cir-ITCH expression was lower in LNCaP and PC-3 cells, compared to the RWPE-1 cell line (Figure 2(b)). Of note, there was no significant difference in the expression of cir-ITCH between the two prostate cancer cell lines.

3.2. cir-ITCH and miR-17 Negatively Interacts in PCa. To verify the interaction between cir-ITCH and miR-17, we examined the expression of cir-ITCH or miR-17 in prostate cancer cell lines and RWPE-1 cell line treated with different agents of transfection using qRT-PCR. As shown in Figure 3, we observed a...
reciprocal inhibition between cir-ITCH and miR-17. Compared with GFP transfection, miR-17 significantly decreased the expression of cir-ITCH in LNCaP and PC-3 cells. Furthermore, cotransfection with miR-17 and cir-ITCH significantly attenuated the enhancing effect caused by transfection with cir-ITCH alone (Figures 3(a) and 3(b)). In turn, overexpression of cir-ITCH inhibited the expression of miR-17 and counteracted its effect in both LNCaP and PC-3 cells (Figures 3(c) and 3(d)).

3.3. cir-ITCH Inhibits the Progression of PCa Cells In Vitro. Functionally, CCK-8 assays revealed that the viability of LNCaP and PC-3 cells decreased in the cir-ITCH overexpression group compared with that in the GFP group (Figures 4(a) and 4(b)). Transfection of miR-17 significantly promoted the viability of both cell lines (Figures 4(c) and 4(d)). The tumor-suppressive effect of cir-ITCH was blocked by miR-17 cotransfection (Figures 4(e) and 4(f)). Meanwhile, Transwell invasion assays indicated that the invasion abilities of LNCaP and PC-3 cell lines were suppressed by the overexpression of cir-ITCH, which was in accordance with the wound-healing assay results (Figure 5). miR-17 mimics could partly attenuate the inhibition of migration and invasion that was mediated by cir-ITCH overexpression in PCa cells.

**Figure 3:** cir-ITCH and miR-17 inhibited each other. The expression of cir-ITCH in LNCaP cells (a) and PC-3 cells (b) treated with different transfection agents (GFP, miR-17, cir-ITCH, and cir-ITCH + miR-17) (***P < 0.01, Student’s t-test). The expression of miR-17 in LNCaP cells (c) and PC-3 cells (d) treated with different transfection agents (GFP, cir-ITCH, miR-17, and cir-ITCH + miR-17) (***P < 0.01, Student’s t-test).
Figure 4: The effects of cir-ITCH or miR-17 on the viability of PCa cell lines. Overexpression of cir-ITCH significantly inhibited the viabilities of LNCaP (a) and PC-3 (b) cells compared with GFP-transfected cells (\(\ast\ast P < 0.01\), Student’s t-test). miR-17 significantly promoted the viabilities of LNCaP (c) and PC-3 (d) cells (\(\ast\ast\ast P < 0.01\), Student’s t-test). Viabilities of PCa cells cotransfected with cir-ITCH and miR-17 were comparable to viabilities of GFP-transfected cells (e, f) (ns: no significance; Student’s t-test).
Figure 5: Continued.
3.4. cir-ITCH Is Involved in the Regulation of the Wnt/β-Catenin and PI3K/AKT/mTOR Signaling Pathways. We investigated key proteins of the pathways in which cir-ITCH may probably participate. Levels of β-catenin, AKT, p-AKT, mTOR, and p-mTOR in cells treated with different agents were analyzed using western blot. As shown in Figure 1, there was an obvious decrease in β-catenin, p-AKT, and p-mTOR in cir-ITCH-overexpressed prostate cancer cells, and in both androgen receptor-positive LNCaP cells and androgen receptor-negative PC-3 cells. However, there was no obvious change in AKT and mTOR expression in the different groups. Additionally, in LNCaP cells, DHT treatment increased the expression of β-catenin, p-AKT, and p-mTOR, while Casodex treatment inhibited the expression of these proteins. On the other hand, in PC3 cells, DHT and Casodex treatments did not impact the expression of these proteins.

4. Discussion

Most cases of prostate cancer will progress into CRPC after a period of androgen deprivation treatment, and the average survival for patients with CRPC is 2–3 years [14]. The mechanism of CRPC has not yet been fully demonstrated.

The Wnt/β-catenin and PI3K/AKT/mTOR pathways were reported to play critical roles in the growth of CRPC. β-Catenin can directly bind to AR to enhance its transcriptional activity in LNCaP cells [15]. Furthermore, nuclear β-catenin can augment the activity of AR in the absence of androgen [16]. β-Catenin is a coactivator of AR, and activation of Wnt/β-catenin signaling was thought to account for CRPC growth [17] and progress of prostate cancer [18]. Wnt/β-catenin inhibitor can increase sensitivity of androgen-independent prostate cancer cells to the second-generation androgen receptor antagonist, enzalutamide, suggesting the therapeutic potential of this approach [19, 20]. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is another important signaling pathway in prostate carcinogenesis [21]. AKT and mTOR are important downstream targets of PI3K, activated by phosphorylation. Studies have shown that activation of the PI3K/AKT signaling pathway can promote prostate cancer cell invasion [22] and the PI3K/AKT/mTOR pathway is associated with advanced prostate cancer and bone metastasis [23]. Notably, there is an interaction between the PI3K/AKT/mTOR and AR pathways. Long-term androgen deprivation treatment can lead to resistance of tumor cells to apoptosis because of the activation of the PI3K/AKT pathway [24]. On the other hand, inhibition of the PI3K/AKT pathway leads to the activation of the AR pathway. Thus, simultaneous inhibition of these two pathways has achieved significant antitumor effects [25].

Although the Wnt/β-catenin and PI3K/AKT/mTOR pathways are essential for the growth of CRPC, their roles still mainly rely on interaction with the androgen receptor axis. During the progression of CRPC, a subtype of PCa undergoes divergent clonal evolution and becomes truly androgen receptor-independent [26]. Therefore, novel-targeted treatments are needed.

Circular RNAs (circRNAs) were presented as a new class of pervasive RNA with regulatory potential; they can bind to microRNAs (miRs) as a competing endogenous RNA (ceRNA), thereby repressing miR function. Hundreds of circRNAs expressed in normal tissues and prostate cancer have been identified [27]. The higher expression of circ-MTO1 in tumor tissue compared to normal tissues suggests a better prognosis. Overexpression of circ-MTO1 in prostate cancer cells can inhibit cell...
viability and the expression of miR-17 [28]. circRNA cir-
cf003 reportedly promotes the development of prostate
cancer by sponging miR-29a-3p [29], while circSMARCS
is upregulated in prostate cancer and its expression is
androgen-responsive [30].

cir-ITCH is a well-known tumor-suppressing circRNA
generated from several exons of itchy E3 ubiquitin protein
ligase (ITCH), which is downregulated in colorectal cancer
[8], lung cancer [9], esophageal squamous cell carcinoma
[10], and bladder cancer [11], and serves as a sponge for
certain miRNAs, including miR-17 and miR-214 [11, 31].
However, the role of cir-ITCH in prostate cancer, espe-
cially in CRPC, has not been well described. In the present
study, we found that cir-ITCH expression was signifi-
cantly downregulated in both PCa tissues as well as PCa cell
lines. Overexpression of cir-ITCH inhibited the growth,
migration, and invasion of PCa cells, proving its tumor
inhibitory function in PCa. Both tumor-promoting as well
as tumor-suppressing roles in PCa have been reported for
miR-17 [28, 32]. Evidence has shown that high or low
miR-17 expression in the blood is related to the progres-
sion of PCa [33]. The results of the present study showed
that miR-17 exerted a tumor-promoting effect in PCa that
could be offset by cir-ITCH. Therefore, we can conclude
that cir-ITCH possibly inhibits prostate cancer by spong-
ing miR-17, which is consistent with the literature [34].

cir-ITCH plays a tumor-suppressing role through inhi-
bition of the Wnt/β-catenin pathway in several neoplasms
[8–11]. We found decreased expression of p-AKT and p-
mTOR in cir-ITCH-overexpressing PCa cells, which indi-
cated that cir-ITCH may also inhibit the PI3K/AKT/m-
TOR pathway. More importantly, cir-ITCH inhibited
representative proteins of the Wnt/β-catenin and PI3K/AKT/mTOR pathways in PC3 cells, which do not express AR and represent androgen receptor-negative
PCa. Thus, we expect future research efforts to explore
cir-ITCH as a new potential therapeutic target in PCa.

5. Conclusions

Our study investigated the role and mechanism of cir-
ITCH in PCa and provided evidence indicating that cir-
ITCH functions as tumor suppressor in prostate cancer
cells via the Wnt/β-catenin and PI3K/AKT/mTOR path-
ways in an AR-independent manner. Our findings may
provide a potential therapeutic target for the management
of PCa, especially CRPC.

Data Availability

The data used to support the findings of this study are avail-
able from the corresponding author upon request.

Conflicts of Interest

The author declares that there are no conflicts of interest.

Acknowledgments

This work was supported by the Youth Talent Training
Project Fund of Hebei General Hospital. The authors
would like to express their gratitude to Editage (https://
www.editage.cn/) for the expert linguistic services pro-
vided. The authors thank Dr. Wang, Department of Sci-
ence and Education, Hebei General Hospital, for English
language editing of the professional content.

References

[1] H. Suzuki, T. Ueda, T. Ichikawa, and H. Ito, “Androgen re-
tector involvement in the progression of prostate cancer,” Endo-
ocrine-Related Cancer, vol. 10, no. 2, pp. 209–216, 2003.
[2] G. Brooke and C. Bevan, “The role of androgen receptor muta-
tions in prostate cancer progression,” Current Genomics, vol. 10, no. 1, pp. 18–25, 2009.
[3] X. Yuan, C. Cai, S. Chen, S. Chen, Z. Yu, and S. P. Balk,
“Androgen receptor functions in castration-resistant prostate
cancer and mechanisms of resistance to new agents targeting the
androgen axis,” Oncogene, vol. 33, no. 22, pp. 2815–2825, 2014.
[4] C. Bo, Y. Qi, G. Zhang, D. Xu, and D. Yan, “Androgen receptor
splice variants activating the full-length receptor in mediating
resistance to androgen-directed therapy,” Oncotarget, vol. 5, no. 6, pp. 1646–1656, 2014.
[5] C. Guo, S. Yeh, Y. Niu et al., “Targeting androgen receptor ver-
sus targeting androgens to suppress castration resistant pros-
tate cancer,” Cancer Letters, vol. 397, pp. 133–143, 2017.
[6] S. Qu, X. Yang, X. Li et al., “Circular RNA: a new star of non-
coding RNAs,” Cancer Letters, vol. 365, no. 2, pp. 141–148, 2015.
[7] L.-L. Chen, “The biogenesis and emerging roles of circular
RNAs,” Nature Reviews Molecular Cell Biology, vol. 17, no. 4, pp. 205–211, 2016.
[8] G. Huang, H. Zhu, Y. Shi, W. Wu, H. Cai, and X. Chen, “cir-
ITCH plays an inhibitory role in colorectal cancer by regulat-
ing the Wnt/β-catenin pathway,” Plos One, vol. 10, no. 6, arti-
cle e0131225, 2015.
[9] L. Wan, L. Zhang, K. Fan, Z. X. Cheng, Q. C. Sun, and J. J.
Wang, “Circular RNA-ITCH suppresses lung cancer prolif-
eration via inhibiting the Wnt/β-catenin pathway,” BioMed
research international, vol. 2016, Article ID 1579490, 11
pages, 2016.
[10] F. Li, L. Zhang, W. Li et al., “Circular RNA ITCH has inhibi-
tory effect on ESCC by suppressing the Wnt/β-catenin path-
way,” Oncotarget, vol. 6, no. 8, pp. 6001–6013, 2015.
[11] C. Yang, W. Yuan, X. Yang et al., “Circular RNA circ-ITCH
inhibits bladder cancer progression by sponging miR-
17/miR-224 and regulating p21, PTEN expression,” Molecular
Cancer, vol. 17, no. 1, p. 19, 2018.
[12] Y. Cheng, X. Yang, X. Deng et al., “MicroRNA-218 inhibits
bladder cancer cell proliferation, migration, and invasion by
targeting BMI-1,” Tumor Biology, vol. 36, no. 10, pp. 8015–
8023, 2015.
[13] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene
expression data using real-time quantitative PCR and the 2−
ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
[14] H. Beltran, T. M. Beer, M. A. Carducci et al., “New therapies
for castration-resistant prostate cancer: efficacy and safety,”
European Urology, vol. 60, no. 2, pp. 279–290, 2011.
[15] C. I. Truica, S. Byers, and E. P. Gelmann, “Beta-catenin affects androgen receptor transcriptional activity and ligand specificity,” Cancer Research, vol. 60, no. 17, pp. 4709–4713, 2000.
[16] D. R. Chesire and W. B. Isaacs, “Beta-catenin signaling in prostate cancer: an early perspective,” Endocrine-Related Cancer, vol. 10, no. 4, pp. 537–560, 2004.
[17] A. de la Taille, M. A. Rubin, M. W. Chen et al., “Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells,” Clinical Cancer Research, vol. 9, no. 5, pp. 1801–1807, 2003.
[18] G. Chen, N. Shukeir, A. Potti et al., “Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications,” Cancer: Interdisciplinary International Journal of the American Cancer Society, vol. 101, no. 6, pp. 1345–1356, 2014.
[19] Z. Zhang, L. Cheng, J. Li et al., “Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer cells,” Cancer Research, vol. 78, no. 12, pp. 3147–3162, 2018.
[20] E. Lee, S. Ha, and S. K. Logan, “Divergent androgen receptor and beta-catenin signaling in prostate cancer cells,” Plos One, vol. 10, no. 10, article e0141589, 2015.
[21] E. C. Lien, C. C. Dibble, and A. Toker, “PI3K signaling in cancer: beyond AKT,” Current Opinion in Cell Biology, vol. 45, pp. 62–71, 2017.
[22] S. Shakla, G. T. MacLennan, D. J. Hartman, P. Fu, M. I. Resnick, and S. Gupta, “Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion,” International Journal of Cancer, vol. 121, no. 7, pp. 1424–1432, 2007.
[23] W. Zhu, X. Hu, J. Xu, Y. Cheng, Y. Shao, and Y. Peng, “Effect of PI3K/Akt signaling pathway on the process of prostate cancer metastasis to bone,” Cell Biochemistry and Biophysics, vol. 72, no. 1, pp. 171–177, 2015.
[24] K. Pfeil, I. E. Eder, T. Putz et al., “Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells,” The Prostate, vol. 58, no. 3, pp. 259–268, 2004.
[25] M. Kato, C. A. Banuelos, Y. Imamura et al., “Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer,” Clinical Cancer Research, vol. 22, no. 11, pp. 2744–2754, 2016.
[26] H. Beltran, D. Prandi, J. M. Mosquera et al., “Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer,” Nature Medicine, vol. 22, no. 3, pp. 298–305, 2016.
[27] S. Chen, V. Huang, X. Xu et al., “Widespread and functional RNA circularization in localized prostate cancer,” Cell, vol. 176, no. 4, pp. 831–843.e22, 2019.
[28] Y. Hu and B. Guo, “Circ-MTO1 correlates with favorable prognosis and inhibits cell proliferation, invasion as well as miR-17-5p expression in prostate cancer,” Journal of Clinical Laboratory Analysis, vol. 34, no. 3, article e23086, 2020.
[29] Z. Kong, X. Wan, Y. Lu et al., “Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p,” Journal of Cellular and Molecular Medicine, vol. 24, no. 1, pp. 799–813, 2020.
[30] Z. Kong, X. Wan, Y. Zhang et al., “Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer,” Biochemical and Biological Research Communications, vol. 493, no. 3, pp. 1217–1223, 2017.
[31] F. Li, K. Ma, M. Sun, and S. Shi, “Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expression,” American Journal of Translational Research, vol. 10, no. 5, pp. 1373–1386, 2018.
[32] R. Ottman, J. Levy, W. E. Grizzle, and R. Chakrabarti, “The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer,” Oncotarget, vol. 7, no. 45, pp. 73739–73753, 2016.
[33] G. Dyson, B. Farran, S. Bolton et al., “The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer,” American Journal of Cancer Research, vol. 8, no. 10, pp. 2088–2095, 2018.
[34] X. Wang, R. Wang, Z. Wu, and P. Bai, “Circular RNA ITCH suppressed prostate cancer progression by increasing HOXB13 expression via spongy miR-17-5p,” Cancer Cell International, vol. 19, no. 1, pp. 1–11, 2019.